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We investigated to what extent maternally derived antibodies interfere with foot-and-
mouth disease (FMD) vaccination in order to determine the factors that influence the 
correct vaccination for piglets. Groups of piglets with maternally derived antibodies were 
vaccinated at different time points following birth, and the antibody titers to FMD virus 
(FMDV) were measured using virus neutralization tests (VNT). We used 50 piglets from 
5 sows that had been vaccinated 3 times intramuscularly in the neck during pregnancy 
with FMD vaccine containing strains of FMDV serotypes O, A, and Asia-1. Four groups of 
10 piglets were vaccinated intramuscularly in the neck at 3, 5, 7, or 9 weeks of age using 
a monovalent Cedivac-FMD vaccine (serotype A TUR/14/98). One group of 10 piglets 
with maternally derived antibodies was not vaccinated, and another group of 10 piglets 
without maternally derived antibodies was vaccinated at 3 weeks of age and served as a 
control group. Sera samples were collected, and antibody titers were determined using 
VNT. In our study, the antibody responses of piglets with maternally derived antibodies 
vaccinated at 7 or 9  weeks of age were similar to the responses of piglets without 
maternally derived antibodies vaccinated at 3  weeks of age. The maternally derived 
antibody levels in piglets depended very strongly on the antibody titer in the sow, so the 
optimal time for vaccination of piglets will depend on the vaccination scheme and quality 
of vaccine used in the sows and should, therefore, be monitored and reviewed on regular 
basis in countries that use FMD prophylactic vaccination.
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inTrODUcTiOn
Foot-and-mouth disease (FMD) is a contagious disease of ruminants and pigs caused by FMD 
virus (FMDV). The disease is considered a major threat to commercially kept ruminants and 
pigs. As  transmission of FMD occurs even when animal movement is prohibited, the major 
transmission routes most likely include people moving between farms. “Stamping out” in a small 
radius around infected farms has recently been applied in several outbreaks, but this involves 
many people moving between potentially infected farms. Therefore, a control measure that 
requires fewer people, such as vaccination, is preferred. Furthermore, from an ethical point of 
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view, vaccination is preferred to stamping out farms at risk (1). 
However, maternally derived antibodies can interfere with the 
development of vaccine-induced immunity (2, 3). There has 
been discussion whether FMDV oil vaccines in pigs can induce 
immunity irrespective of maternally derived antibodies but 
Francis and Black (4) showed that maternally derived antibodies 
hinder the development of protective immunity. In cattle, it has 
been shown that a heterologous strain within the same serotype 
can induce an immune response in calves with maternally 
derived antibodies (5), so the immune response is not neces-
sarily blocked by maternally derived antibodies. In addition, in 
pigs with maternally derived antibodies, a response to influenza 
vaccination can also be measured in the presence of maternally 
derived antibodies. However, the response is lower and will 
probably not protect (6). One of the options to boost immunity 
levels is repeated vaccination, i.e., first vaccination in the pres-
ence of maternally derived antibodies, to prime the immune 
system, and a second vaccination 1 or 2 months later. However, 
the costs of two vaccine administrations are high, not only due 
to the cost of vaccine but also the logistics and labor costs, which 
are often higher. Therefore, it may be preferable to optimize the 
timing of a single vaccination.
The objective of this study was to determine the factors that 
influence the optimal age for FMDV vaccination of piglets. We 
measured the neutralizing antibody response in piglets born to 
vaccinated sows at 3, 5, 7, and 9 weeks of age. The neutralizing 
antibody titer was compared with non-vaccinated piglets from 
the same sows, as well as with vaccinated piglets born from non-
immune sows.
MaTerials anD MeThODs
Vaccine
The antigens used in the vaccines in this study were produced 
on an industrial scale using baby hamster kidney (BHK) cells. 
The antigens were inactivated with binary ethyleneimine (BEI) 
and concentrated approximately 100 times by two cycles of poly-
ethylene glycol (PEG) precipitation. The antigen concentration 
was determined by sucrose gradient analysis (7). The oil vaccines 
were formulated using a mineral oil as adjuvant in a double oil 
emulsion, as previously described (8). The vaccines were formu-
lated to contain at least six PD50 per dose (i.e., six times the dose 
that protects 50% of the cattle against virulent challenge in the 
tongue). One trivalent vaccine batch was used for the sows and 
one monovalent vaccine batch was used for the piglets. A single 
dose was 2 ml.
Vaccination of sows
The sows (SPF pigs TN20 and TN70 from the genetics company 
Topigs Norsvin) used in this study were available from a vaccine 
safety test. The sows had not been vaccinated against FMD before 
beginning the study and were free of antibodies against FMDV. 
The sows were vaccinated intramuscularly with trivalent FMDV 
vaccine containing O Manisa, Asia-1 Shamir, and A TUR/14/98 
antigen. The sows were vaccinated at day 36, 57, and 85 of gesta-
tion. Piglets were born after 112–114 days of gestation.
Vaccination Piglets
A total of five vaccinated sows were selected that had nine or 
more piglets. From each sow, two piglets with maternally derived 
antibodies were selected randomly and assigned to one of the five 
groups of piglets (except in Group 5 where one sow supplied three 
piglets and one sow only one piglet). Two non-vaccinated sows 
supplied each five piglets for Group 6 (vaccinated piglets without 
maternally derived antibodies).
Piglets with maternally derived antibodies in Groups 1, 2, 
3, and 4 were vaccinated intramuscularly with a single dose of 
monovalent FMD vaccine containing A TUR/14/98 at 3, 5, 7, and 
9 weeks of age, respectively. The piglets that were used as vaccina-
tion control (Group 6) were vaccinated at 3 weeks of age. Serum 
samples were collected weekly up to 6 weeks after vaccination.
Virus neutralization Test
Sera were tested for virus neutralizing antibodies against FMDV 
A TUR/14/98, O Manisa, and Asia-1 Shamir, using primary por-
cine kidney cells (9). Twofold dilutions of the serum samples were 
tested starting with undiluted serum. Titers were expressed as 
log10 of the reciprocal of the dilution that inhibited virus growth 
in 50% of the wells. For calculation of the mean titers and for the 
use in statistical tests, we used 0 for the observations with a log10 
titer of <0.30.
statistical analysis
Because the same animals were sampled at different time points, 
we analyzed the antibody response in the sows by forward 
selection in a linear mixed-effects model (10, 11) using the virus 
neutralization tests (VNT) titer as continuous response variable, 
the time after vaccination and strains as possible explanatory 
nominal variables. The animal ID was included as random 
variable (model M1). The relation between neutralizing antibody 
titer in the sows 3 weeks after the last vaccination (approximately 
30 weeks of gestation), and the antibody titer in the piglets just 
after colostrum uptake was analyzed by linear regression. Using 
forward selection, the effect of serotype was analyzed (M2).
The median time for which neutralizing antibody titers in 
the piglets were detected (titer ≥0.3) was analyzed in a logistic 
mixed-effects model (10, 11). Whether or not a neutralizing anti-
body titer was observed was the binary result variable. Possible 
nominal explanatory variables used were group, serotype, and 
mother, whereas the possible continuous explanatory variables 
were age and neutralizing antibody titer at birth. The piglet was 
entered as random variable (M3).
The half-life of the neutralizing antibody titers was analyzed 
in a linear mixed-effects model (10, 11). The neutralizing anti-
body titer measured was the result variable. Possible nominal 
explanatory variables used were group, serotype, and mother, 
whereas the possible continuous explanatory variables were age, 
neutralizing antibody titer of the dam, and neutralizing antibody 
titer at birth. The piglet was entered as random variable (M4). In 
the abovementioned analyses, the best fitting model was selected 
in a forward selection procedure using the Aikaike information 
criterion (12, 13). Analysis was performed using R version 3.2.3 
and lme4 library version 1.1.10 using default settings.
TaBle 1 | Final selected linear mixed-effects model (M1) using the VnT 
titer in the sows (n = 5) as continuous response variable, the time after 
vaccination, and strains as possible explanatory nominal variables.
random effects Variance sD
Sow 0.007 0.08
Residual 0.05 0.23
Fixed effects estimate se t-Value
Intercept  −0.3 0.07 −4.5
0.9 weeks post vaccination 0.0 0.08 0.0
1.9 weeks postvaccination 0.6 0.08 7.4
2.9 weeks postvaccination 0.6 0.08 6.8
3.9 weeks postvaccination 0.7 0.08 8.6
4.9 weeks postvaccination 0.8 0.08 9.9
5.9 weeks postvaccination 0.7 0.08 9.0
6.9 weeks postvaccination 0.7 0.08 8.7
7.9 weeks postvaccination 0.9 0.08 10.3
8.9 weeks postvaccination 1.0 0.08 12.4
9.9 weeks postvaccination 0.8 0.08 9.8
Strain A TUR/14/98 0.5 0.04 12.4
Strain O Manisa 0.5 0.04 10.8
The animal was included as random variable.
FigUre 1 | Titers observed in sows (n = 5) vaccinated with trivalent 
FMD vaccine (at least six PD50 per dose) three times during gestation. 
Antigens included in the vaccine were type A TUR/14/98 (diamonds), O 
Manisa (squares), and Asia-1 Shamir (triangles). The arrows indicate the time 
of vaccination. The error bars (only one direction to avoid overlap) indicate 
the SEM.
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resUlTs
The neutralization titers observed in the sows are given in 
Figure 1. The linear mixed-effects model (M1, Table 1) showed 
that the neutralizing antibody response was significantly higher 
2–10  weeks after vaccination compared with the titer at the 
time of vaccination, but differed significantly between strains. 
The titer induced by serotype Asia-1 was approximately 0.5 
log10 lower than the titers against A TUR/14/98 and O Manisa 
(Table 1).
Table  2 shows the neutralizing antibody titers against A 
TUR/14/98 in the piglets in the various groups. In the piglets 
with maternally derived antibodies (Groups 1–5), the mean 
neutralizing antibody titer (log10) against A TUR/14/98 was 1.7 
(SEM 0.05) at birth. The mean neutralizing antibody titer (log10) 
against O Manisa was slightly higher (mean, 2.0 SEM 0.06) and 
lower for serotype Asia-1 Shamir (mean, 1.3 SEM 0.06). The 
neutralizing antibody titer of the piglets was strongly correlated 
with the neutralizing antibody titer of the sows. On average, a 1 
log10 higher antibody titer in the sows resulted in a 1 log10 higher 
antibody titer in the piglets (univariate linear regression, data not 
shown). However, the relation was different for each serotype, 
and an interaction effect was found between serotype and the 
neutralization titer of the dam (M2, Table  3). The interaction 
effect was caused by the fact that the titers in the dam for type A 
TUR/14/98 were 0.9 or 1.05, and no relation between antibody 
titer in the dam and the piglet for this serotype could be deter-
mined (Table 3).
The duration for which maternally derived antibodies could 
be detected differed for the different serotypes (Figure  2). The 
logistic mixed-effects model (M3, Table  4) showed that the 
presence of VNT titres was statistically dependent on the titer 
at birth, age, the serotype with an interaction effect between 
age, and serotype. The median time that antibodies are present 
increases with approximately 29–53 days when the titer at birth 
is 1 log10 higher, depending on the serotype. For piglets with a 
neutralizing antibody titer of 2 log10 at birth (the mean titer for O 
Manisa in the dataset), the model produced a median time that 
neutralizing antibodies could be detected of 9, 14, and 9 weeks, 
respectively, for serotype A TUR/14/98, O Manisa, and Asia-1 
Shamir. Interestingly, when the analysis was performed with only 
the non-vaccinated piglets (Group 5), a significant interaction 
effect between age and serotype was found, indicating that the 
median time for which antibodies are present are different for 
different serotypes even if the piglets were born from the same 
mother and started with the same neutralizing antibody titer at 
birth (results not shown).
The total number of sera tested in Groups 1–5 was 421; the 
number of left censored data (sera with a titer <0.3) was different 
for each serotype 57 for O Manisa, 71 for A TUR/14/98, and 254 
for Asia-1. However, none of the piglets had a titer <0.3 at the 
beginning of the study. In the linear mixed-effects model, to study 
of the decline of neutralizing antibody titers in the piglets (M4, 
Table 5), only sera with a titer of 0.3 or higher were included. 
The analysis showed that the antibody titer depended on the 
age of the piglets, the titer of birth, the titer of the dam, and the 
serotype. There were interaction effects found between serotype 
and age, titer at birth and age, and titer of the sow and serotype. 
The interaction effect between both serotype and titer at birth 
with age shows that half-life of neutralizing antibodies detected in 
our study depends on the serotype and the titer at birth. The esti-
mated half-life of neutralizing antibodies for a piglet that started 
with a neutralizing antibody titer of 2 log10 (based on the observed 
mean titer in week 1 for O Manisa) was 11, 16, and 12 days for, 
respectively, serotype A TUR/14/98, O Manisa, and Asia-1.
TaBle 5 | Final selected linear mixed-effects model (M4) using the VnT 
titer in the piglets (n = 50) as continuous response variable, the age, VnT 
titer at birth, VnT titer of the sows, and strains as possible explanatory 
variables.
random effects Variance sD
Piglet 0.01 0.10
Residual 0.04 0.20
Fixed effects estimate se t-Value
Intercept 0.2 0.07 2.8
Age (days) −0.02 0.002 −8.3
VNT titer at birth 0.8 0.06 12
VNT titer dam 0.4 0.1 3.9
Strain A TUR/14/98 −0.8 0.4 −2.0
Strain O Manisa −0.05 7 −0.8
Interaction age and strain A TUR/14/98 −0.002 0.002 −0.8
Interaction age and strain O Manisa 0.006 0.001 6.4
Interaction age and VNT titer at birth −0.005 0.001 −5.3
Interaction VNT titer dam and strain A 
TUR/14/98
0.8 0.4 1.9
Interaction VNT titer dam and strain O 
Manisa
−0.1 0.09 −1.6
The piglet was included as random variable. Strain Asia-1 was the baseline variable.
TaBle 4 | Final selected logistic mixed-effects model (M3) using the 
presence of a VnT titer (<0.3 is negative, 0.3 or higher is positive) in the 
piglets (n = 50) as binary response variable, the age (days), the VnT titer 
at birth, and strains as possible explanatory variables.
random effects Variance sD
Piglet 2.7 1.7
Fixed effects estimate se z-Value p-Value
Intercept −0.2 0.9 −4.5 0.8
VNT titer at birth 6.5 0.8 8.1 ≪ 0.001
Age (days) −0.2 0.02 −8.8 ≪ 0.001
Strain A TUR/14/98 2.7 2.6 1.0 0.3
Strain O Manisa −1.2 1.2 −0.9 0.3
Interaction age and strain 
A TUR/14/98
−0.4 0.05 −0.8 0.4
Interaction age and strain 
O Manisa
0.1 0.02 3.6 0.0003
The piglet was included as random variable. Strain Asia-1 was the baseline variable.
FigUre 2 | Proportion of piglets with FMDV neutralizing antibody titers 
≥0.3. For non-vaccinated piglets A TUR/14/98 (only Group 5, diamonds, 
central line). For all piglets with maternally derived antibodies (Group 1–5) for 
serotype O Manisa (squares, line on the right) and serotype Asia-1 Shamir 
(triangles, line on the left). The data were analyzed by a logistic mixed-effects 
model. The dashed line indicates the extrapolated part of the curve.
TaBle 3 | Final selected linear model (M2) using the VnT titer at birth of 
the piglets (n = 50) as continuous response variable, the VnT titer of the 
dam and strains as possible explanatory variables.
estimate se t-Value p-Value
Intercept 0.6 0.1 5.5  ≪ 0.001
VNT titer of dam 1.6 0.2 8.3 ≪ 0.001
Strain A TUR/14/98 1.3 0.6 2.2 0.03
Strain O Manisa 0.6 0.2 3.5 0.0006
Interaction VNT titer dam 
and strain A TUR/14/98
−1.7 0.6 −2.9 0.005
Interaction VNT titer dam 
and strain O Manisa
−0.7 0.2 3.2 0.001
Strain Asia-1 was the baseline variable.
TaBle 2 | age and neutralizing antibody titer against the strain used for vaccination (a TUr/14/98).
group number age of vaccination (days) VnT titer (a TUr/14/98) at birth VnT titer (a TUr/14/98) at vaccination
Minimum Mean Maximum Minimum Mean Maximum Minimum Mean Maximum
1 10 21 22 23 0.90 1.7 2.10 0.60 1.2 1.65
2 10 35 36 37 1.35 1.8 2.25 0.45 0.9 1.50
3 10 49 50 51 0.90 1.7 2.25 <0.30 0.5 1.05
4 10 63 64 65 1.35 1.8 2.40 <0.30 0.1 0.60
5 10 NA NA NA 1.35 1.8 2.25 NA NA NA
6 10 20 21 21 <0.3 <0.3 <0.3 <0.3 <0.3 <0.3
Mean titers are calculated considering <0.30 as 0.
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Figure  3 shows the response of the piglets to homologous 
vaccination with a monovalent FMDV serotype A TUR/14/98 
vaccine. The curves show that all groups of piglets respond to vac-
cination; after vaccination, the curve does not follow the decrease 
of maternally derived antibodies observed in non-vaccinated 
piglets. However, piglets vaccinated 4 or 5 weeks after birth did 
not have a response to the vaccine up to the level seen in a previ-
ous study (horizontal dotted line in Figure 3) in which pigs were 
FigUre 3 | FMD type a TUr/14/98 serology profile following homologous vaccination of piglets with maternally derived antibodies. Piglets were either 
vaccinated at 3 (open triangle), 5 (solid circle), 7 (open box), or 9 (solid triangle) weeks of age. One group of piglets (open circle) did not receive a vaccination and 
one group did not have maternally derived antibodies (solid box). The horizontal line indicates the mean virus neutralization titer observed 28 days postvaccination in 
a previous study in pigs vaccinated with a vaccine containing six PD50 per dose.
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vaccinated with an FMD vaccine containing six PD50 per dose. 
The response in the piglets vaccinated 7 and 9 weeks after birth 
was similar to the response observed in pigs vaccinated with an 
FMD vaccine containing six PD50 per dose. Based on this six PD50 
per dose threshold value, the response in the piglets vaccinated 
7 and 9 weeks after birth was deemed sufficient, and the piglets 
vaccinated 9 weeks after birth had an earlier and initially a higher 
response than the piglets born from non-vaccinated sows.
DiscUssiOn
The objective of this study was to determine the optimal age for 
FMD vaccination of piglets based on measurement of serological 
titers following vaccination and the corresponding level of pro-
tection that can be expected. In contrast to an earlier publication 
(4), we observed a response in piglets with maternally derived 
antibodies vaccinated 3 weeks after birth; following vaccination, 
the curve did not follow the decrease of maternally derived anti-
bodies observed in non-vaccinated piglets. In our experiment, 
when considering the six PD50 per dose threshold value (shown 
in Figure  3) the response to vaccination was sufficient when 
piglets were vaccinated 7–9 weeks after birth. Piglets can respond 
to vaccination in the presence of maternally derived antibodies, 
as has been shown before for FMDV vaccines (14), as well as 
for influenza vaccines (6). Our experiment confirms the earlier 
finding that the higher the maternally derived antibody titer, 
the lower the response to vaccination. To induce a neutralizing 
antibody titer likely to confer protection, piglets should ideally 
be vaccinated when maternally derived antibodies are at very 
low level. The median time that maternally derived antibod-
ies are present in piglets depends on the titer at birth and the 
serotype. The titer at birth depends on the titer of the sows and 
the serotype of the vaccine. We observed a large variation in 
antibody titers between seroptypes in the sows, which, in turn, 
resulted in differences between serotypes in maternal antibody 
titers and, consequently, the optimal time for vaccination of 
the piglets. The antibody response for Asia-1 Shamir in pigs 
was known to be lower in comparison to A TUR/14/98 and O 
Manisa (15). It is difficult to extrapolate our findings to other 
FMD vaccines since different vaccine formulations might induce 
higher or lower responses in sows. The vaccination protocol of 
the sows can also influence the outcome. In our case, the sows 
were vaccinated three times during pregnancy, because the 
study was a repeat-dose safety study for a vaccine marketing 
authorization application. In a field situation, it is probably easier 
to vaccinate sows one or two times per year, which will prob-
ably result in higher variation in titers in the piglets compared 
with a scheme suggested earlier (16), where sows are vaccinated 
before pregnancy and boosted once during pregnancy to obtain 
the highest titers in the piglets. Therefore, it is important that 
authorities responsible for vaccination monitor the response and 
study the optimal time for vaccination on a regular basis, as 
different FMD vaccines used in sows can influence the immune 
status of the mother.
A remarkable finding in both the logistic mixed-effects 
model and the linear mixed-effects model was the interaction 
effect between age and serotype. In the linear mixed-effects 
model, this interaction could be explained in the difference in 
censoring for the different serotypes; for serotype Asia-1, there 
were more observations with a VNT titer <0.3. In the logistic 
mixed-effects model, there was no censoring. This indicates 
that the decrease of maternally derived antibodies was differ-
ent between the different serotypes. Such an interaction effect 
was not observed when we studied the duration of maternally 
derived antibodies in calves (5). The difference can be explained 
by the fact that decrease of maternally derived antibodies is not 
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only due to antibody metabolism but also due to the growth 
of the piglet (3), in combination with the fact that the titers at 
birth were not the same. The biggest change in weight (rela-
tively) is in the beginning, when piglets grow from 1–2 kg to 
approximately 10 kg within a month. This is almost a 10-fold 
increase in weight. The next 10-fold increase takes more than 
5  months. In the profile of the O Manisa, maternally derived 
antibody titers, approximately a 1 log10 decrease is seen in the 
first 4 weeks, then the decrease becomes less steep. For serotype 
Asia-1 and the non-vaccinated piglets for A TUR/14/98, a 1 log10 
decrease is also observed in the same period. But for serotype 
Asia-1, most piglets have titers below the detection level of the 
assay after 4  weeks (Figure  2), so it is not possible to assess 
the reduction in slope. It is unlikely that the metabolization of 
maternally derived antibodies is different between the different 
serotypes.
The antibody response in this study was only followed for 
6 weeks after vaccination, but fattening pigs should be protected 
for at least 6 months. Therefore, it is advisable that further studies 
in countries using vaccination are carried out, also to obtain data 
on antibody response in a field situation.
The most important result from our study was the observa-
tion that large differences arise in the duration of the maternally 
derived antibodies, which mainly depend on the titer at birth, 
which, in turn, depends on the titer in the sows. Therefore, 
every country that uses vaccination to control FMD in swine 
populations should determine the optimal vaccination strategy 
for the vaccine they are using monitoring titers in sows. A reas-
sessment of the strategy is warranted when new FMD vaccines 
are introduced.
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